Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
Subscribe to ACCEL Lite
Other ACC resources on DAPT and bleeding risk:
1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
3. ACC.24 Presentation Slides | ULTIMATE-DAPT
View all episodes
By American College of Cardiology
3.7
5353 ratings
Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
Subscribe to ACCEL Lite
Other ACC resources on DAPT and bleeding risk:
1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
3. ACC.24 Presentation Slides | ULTIMATE-DAPT
131 Listeners
325 Listeners
161 Listeners
865 Listeners
496 Listeners
281 Listeners
3,336 Listeners
90 Listeners
138 Listeners
1,095 Listeners
39 Listeners
185 Listeners
349 Listeners
427 Listeners
37 Listeners